ADOCIA Announces Three Presentations at the American Diabetes Association 84th Scientific Sessions
-
Exclusive non-clinical data have been selected for presentations at
ADA on three of Adocia’s innovative programs:- AdoShell®, aimed as a curative treatment for people with Type 1 Diabetes by delivering human islets or iPSCs1, is progressing towards a First-In-Human trial
- AdOral® is an oral delivery technology, that could improve bioavailability of semaglutide over Rybelsus®, and applicable to a wide range of therapeutic peptides
- AdoGel® could ensure a sustained release of semaglutide with a once monthly injection, offering an alternative to today’s once weekly injection
The annual meeting of the
The abstracts are published online on the journal Diabetes® website and the ePoster presentations will be available to conference attendees from
- AdoShell®, a non-fibrotic encapsulation system for human islets transplantation shows promising results for clinical application as a cure for people with Type 1 Diabetes
-
Presentation 1504-P:
Saturday, June 22 ,12:30 pm-1:30 pm (ET)
AdoShell® is an easily implantable and fully retrievable scaffold for islet transplantation aiming to cure diabetes by cell therapy without requiring immunosuppression. It is based on a permselective hydrogel film allowing insulin diffusion while preventing immune cell invasion. Allogenic transplant of rat islets in immunocompetent diabetic rats has already demonstrated encapsulated islets survival, insulin secretion, and glycemic regulation.
Compatibility with human islets, local tolerance, and scalability to deliver a therapeutic dose were studied to meet requirements for a first in human. Findings of these studies demonstrate that AdoShell® Islets is suitable for clinical evaluation.
- AdOral®, a versatile platform for improved oral peptide absorption
-
Presentation 1677-P:
Monday, June 24 ,12:30 pm - 01:30 pm (ET)
AdOral® is an oral delivery platform based on non-specific Mechanism of Action (MoA) via intestine paracellular passage leading to improved absorption. AdOral®‘s MoA and its permeation effect were evaluated in vitro and in vivo on several peptides, including semaglutide, and compared to SNAC (the technology used in Rybelsus®). AdOral® is a versatile and performant platform that could lead to oral formulations for a wide range of therapeutic peptides.
- Development of a once-a-month formulation of Semaglutide from an innovative injectable and biodegradable hydrogel
-
Presentation 1674-P:
Monday, June 24 ,12:30 pm - 1:30 pm (ET)
AdoGel® is an injectable hydrogel technology consisting of cross-linked degradable polymers that allows sustained release of soluble peptides over 1 to 3 months duration. An AdoGel® formulation of semaglutide was tested in rats. Results showed that a sustained release of semaglutide over one month is achievable and could be a real benefit for patient compliance by limiting the injection frequencies, reducing side effects and improving efficacy.
Note: all information contained in the submitted abstract should be considered preliminary and subject to change until the study data and observations are fully presented at the
About the American Diabetes Association Scientific Sessions
The American Diabetes Association’s Scientific Sessions is the world’s largest diabetes meeting, convening more than 11,000 leading physicians, scientists, researchers and health care professionals from around the globe. The meeting features the latest scientific findings in diabetes, including more than 200 sessions and 2,000 original research presentations.
About
The company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) The BioChaperone® technology for the development of new generation insulins and products combining different hormones; 2) AdOral®, an oral peptide delivery technology; 3) AdoShell®, an immunoprotective biomaterial for cell transplantation, with an initial application in pancreatic cells transplantation; and 4) AdoGel®, a long-acting drug delivery platform.
Disclaimer
This press release contains certain forward-looking statements concerning
The forward-looking statements contained in this press release are also subject to risks not yet known to
____________
1 iPSCs: induced pluripotent stem cells
View source version on businesswire.com: https://www.businesswire.com/news/home/20240618032710/en/
CEO
contactinvestisseurs@adocia.com
+33 (0)4 72 610 610
www.adocia.com
Ulysse Communication
adocia@ulysse-communication.com
+ 33 (0)6 87 88 47 26
Source: